article thumbnail

MERS DNA vaccine induces immunity, protects from virus challenge in preclinical model

Scienmag

Dose-sparing regimens and intradermal delivery have important implication for rapid clinical development of effective, well-tolerated and easy-to-distribute vaccines against MERS and other emerging coronaviruses.

DNA 61
article thumbnail

Symvivo’s Oral COVID-19 Vaccine Enters Clinical Trials

XTalks

Canadian clinical-stage biotech company Symvivo Corporation has developed an oral COVID-19 vaccine that entered clinical trials this week. The first healthy volunteer was dosed with the vaccine in Australia as part of the bacTRL-Spike COVID-19 Phase I clinical trial.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Cancer Research UK, University of Southampton and Touchlight Genetics Partner to Develop Head and Neck Cancer Vaccine

Drug Discovery Today

Cancer Research UK, the University of Southampton and Touchlight Genetics, a London based biotechnology company, today (Wednesday) announce a new clinical development partnership to progress a therapeutic DNA vaccine, TGL-100, into an early phase clinical trial targeting head and neck squamous cell carcinoma (HNSCC).

article thumbnail

Gene Therapy and Pharmacokinetics

Camargo

Gene therapy, which was in its infancy around 30 years ago, is now becoming a more prominent treatment method in many therapeutic areas, from personalized therapy to mass vaccinations against COVID-19. PK Planning for Gene Therapy Development Programs. Additionally, gene editing allows us either to remove or to modify harmful genes.

article thumbnail

AstraZeneca takes COVID-19 vaccine to China with BioKangtai deal for 200M-dose capacity by 2021

The Pharma Data

We pointed out last week that China was a notable missing element in AstraZeneca’s COVID-19 vaccine strategy, despite being the drugmaker’s second-largest market. The pair will also explore the possibility of producing the vaccine for other markets. The vaccine was moved into phase 2/3 in May. That has changed.

article thumbnail

In The Global Race For The COVID-19 Vaccine, India Stands As A Strong Player

Delveinsight

Today the whole world is in a search for an effective vaccine candidate against SARS-CoV-2. The vaccine appears to be the only solution to prevent coronavirus. Several pharma and biotech companies are developing and manufacturing safe and effective vaccines to fight coronavirus. India’s COVID-19 vaccine candidates.

article thumbnail

Astellas takes $170m charge as it drops DMD gene therapies

pharmaphorum

The write-down comes in the wake of problems affecting the Japanese drugmaker’s AT132 gene therapy candidate for rare disease X-linked myotubular myopathy (XLMTM), which was placed on clinical hold by the FDA last year after four patient deaths liked to possible liver-related side effects.